Maximum Signaling for Maximum Regeneration

Caution – be careful what you use:

Predictive Biotech single material Wharton jelly independent lab test by Dr. Spencer shows only 2.4% viability. See Predictive screen shot.
Also, the test showed only 2/3 the quantity of cells versus what is promoted. Click here to see the video.
Predictive Biotech Falls

Bone marrow cell extraction has resulted in serious infections and the cell counts reduce dramatically with age. See the chart in our brochure. Adipose cell extraction has resulted in adverse reactions causing blindness and stroke. Both procedures cause patient discomfort.

Is bone marrow surgery risky? NJ Principal dies donating bone marrow. Do bone marrow extraction practices follow processing and labeling FDCA and PHSA regulations? See United States of America v. Regenerative Sciences, LLC No. 12-5254 Appellate Ruling dated February 4, 2014.

Utah Cord Bank lab test tissue clump debris in photo. Test shows no viability.

Mimedx Injectables Do Not Meet FDA Standards – WSJ article.

Umbilical cord blood myths and side effects.

Umbilical cord blood product by Liveyon recalled. Product does not have MSCs? Counts are heavily marketed although not allowed by the FDA.

Please see RICHGEN report on Maximum Signaling for Maximum Regeneration about potency is more important than counts.

Efficacy of PRP Study: No improvement

FDA rules exosomes products being sold are not licensed and approved.
FDA Public Safety Notice Bans Exosome Products.

FDA Issues Kimera Labs Warning

FDA Warns Invitrx of Violations, Deviations and Claims

Concerning Invitrx Inspection Report

FDA Bans Cultured Exosomes

FDA Letter to Kimera Labs

RichSource is rapidly educating practitioners who are ready to replace risky, time consuming and outdated techniques. In addition, the RichSource superior products are umbilical cord blood free. Our standards are very advanced in producing the most reliable injectables in full compliance.

The Facts About Bone Marrow Aspirate

See Regenexx: United States of America v. Regenerative Sciences, LLC No. 12-5254 Appellate Ruling dated February 4, 2014.

Caution – be careful what you use:

Predictive Biotech Wharton jelly product viability independent testing is only 2.4% versus what is claimed per Dr. Eliott Spencer, PhD.

Bone marrow cell extraction has resulted in serious infections and the cell counts reduce dramatically with age. See the chart in our brochure. Adipose cell extraction has resulted in adverse reactions causing blindness and stroke. Both procedures cause patient discomfort.

Is bone marrow surgery risky? NJ Principal dies donating bone marrow. Do bone marrow extraction practices follow processing and labeling FDCA and PHSA regulations? See United States of America v. Regenerative Sciences, LLC No. 12-5254 Appellate Ruling dated February 4, 2014.

Utah Cord Bank lab test tissue clump debris in photo.

Mimedx Injectables Do Not Meet FDA Standards – WSJ article.

Efficacy of PRP Study: No improvement

Umbilical Cord “Stem Cell” Infusion Side Effects: What you need to know…